

COLUMBIA LABORATORIES INC  
Form SC 13G/A  
February 13, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 2)\***

**COLUMBIA LABORATORIES, INC.**

**(Name of Issuer)**

**Common Stock, Par Value \$0.01 Per Share**

**(Title of Class of Securities)**

**197779101**

**(CUSIP Number)**

**DECEMBER 31, 2013**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

“ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 2 of 22 Pages

1 Names of reporting persons

ACTAVIS PLC

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

IRELAND

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 3 of 22 Pages

1 Names of reporting persons

WARNER CHILCOTT PLC

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

IRELAND

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 4 of 22 Pages

1 Names of reporting persons

ACTAVIS WC 1 S.À R.L.

2 Check the appropriate box if a member of a group (see instructions)

(a) " (b) "

3 SEC use only

4 Citizenship or place of organization

LUXEMBOURG

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) "

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.



SCHEDULE 13G/A

CUSIP No.: 197779101

Page 5 of 22 Pages

1 Names of reporting persons

ACTAVIS WC 2 S.À R.L.

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

LUXEMBOURG

Number of  5 Sole voting power

shares  6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1) (2)</sup>

each  7 Sole dispositive power

reporting  8 Shared dispositive power

person

with: 1,400,000 <sup>(1) (2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1) (2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 6 of 22 Pages

1 Names of reporting persons

ACTAVIS IRELAND HOLDING LIMITED

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

IRELAND

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 7 of 22 Pages

1 Names of reporting persons

ACTAVIS CAPITAL S.À R.L.

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

LUXEMBOURG

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1) (2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1) (2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1) (2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 8 of 22 Pages

1 Names of reporting persons

ACTAVIS W.C. HOLDING INC.

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

DELAWARE

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

CO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.



SCHEDULE 13G/A

CUSIP No.: 197779101

Page 9 of 22 Pages

1 Names of reporting persons

ACTAVIS, INC.

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

NEVADA

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

CO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 10 of 22 Pages

1 Names of reporting persons

WATSON LABORATORIES, INC.

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

DELAWARE

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

CO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 11 of 22 Pages

1 Names of reporting persons

COVENTRY ACQUISITION, LLC

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

DELAWARE

Number of 5 Sole voting power

shares 6 Shared voting power

beneficially

owned by 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

each 7 Sole dispositive power

reporting 8 Shared dispositive power

person

with: 1,400,000 <sup>(1)</sup> <sup>(2)</sup>

9 Aggregate amount beneficially owned by each reporting person

1,400,000 <sup>(1)</sup> <sup>(2)</sup>

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

11.7%<sup>(3)</sup>

12 Type of reporting person (see instructions)

OO

- (1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.
- (2) Shared with the other Reporting Persons solely by virtue of the fact that Coventry Acquisition, LLC, the record holder of the shares, is an indirect subsidiary of Actavis plc and a direct or indirect subsidiary of the other Reporting Persons as more fully described under Item 4 herein.
- (3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

## SCHEDULE 13G/A

CUSIP No.: 197779101

Page 12 of 22 Pages

**Item 1(a). Name of Issuer:** Columbia Laboratories, Inc.**Item 1(b). Address of Issuer's Principal Executive Offices:**

4 Liberty Square, Fourth Floor  
Boston, Massachusetts 02109

**Item 2(a). Name of Person(s) Filing:**

Actavis plc	( Actavis plc )
Warner Chilcott plc	( Warner Chilcott )
Actavis WC 1 S.à r.l.	( WC 1 S.à r.l. )
Actavis WC 2 S.à r.l.	( WC 2 S.à r.l. )
Actavis Ireland Holding Limited	( Actavis Ireland )
Actavis Capital S.à r.l. (formerly Actavis WC Holding S.à r.l.)	( Actavis Capital )
Actavis W.C. Holding Inc.	( Actavis W.C. )
Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.)	( Actavis, Inc. )
Watson Laboratories, Inc.	( Watson Labs )
Coventry Acquisition, LLC	( Coventry LLC )

**Item 2(b). Address of Principal Business Office or, if none, Residence:**

Actavis plc  
1 Grand Canal Square, Docklands  
Dublin 2, Ireland

Warner Chilcott  
1 Grand Canal Square, Docklands  
Dublin 2, Ireland

WC 1 S.à r.l.  
46A, avenue J.F. Kennedy  
L-18555 Luxembourg  
Grand Duchy of Luxembourg

WC 2 S.à r.l.  
46A, avenue J.F. Kennedy  
L-18555 Luxembourg  
Grand Duchy of Luxembourg

Actavis Ireland  
70 Sir John Rogerson's Quay  
Dublin 2, Ireland

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 13 of 22 Pages

Actavis Capital  
 46A, avenue J.F. Kennedy  
 L-18555 Luxembourg  
 Grand Duchy of Luxembourg

Actavis W.C.  
 Morris Corporate Center III  
 400 Interpace Parkway  
 Parsippany, New Jersey 07054

Actavis, Inc.  
 Morris Corporate Center III  
 400 Interpace Parkway  
 Parsippany, New Jersey 07054

Watson Labs  
 577 Chipeta Way  
 Salt Lake City, Utah 84108

Coventry LLC  
 577 Chipeta Way  
 Salt Lake City, Utah 84108

**Item 2(c). Citizenship:**

Actavis plc:	Ireland
Warner Chilcott plc	Ireland
WC 1 S.à r.l.	Luxembourg
WC 2 S.à r.l.	Luxembourg
Actavis Ireland	Ireland
Actavis Capital	Luxembourg
Actavis W.C.	Delaware
Actavis, Inc.:	Nevada
Watson Labs:	Delaware
Coventry LLC:	Delaware

**Item 2(d). Title of Class of Securities:**

Common Stock, par value \$0.01 per share

**Item 2(e). CUSIP Number:** 197779101

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:** Not applicable.



## SCHEDULE 13G/A

CUSIP No.: 197779101

Page 14 of 22 Pages

**Item 4. Ownership:**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

As to each of the following entities (as defined under Item 2(a) herein):

**Actavis plc****Warner Chilcott****WC 1 S.à r.l.****WC 2 S.à r.l.****Actavis Ireland****Actavis Capital****Actavis W.C.****Actavis, Inc.****Watson Labs****Coventry LLC**

(a) Amount beneficially owned:	1,400,000 <sup>(1)</sup>
(b) Percent of class:	11.7% <sup>(3)</sup>
(c) Number of shares as to which such person has:	
(i) Sole power to vote or to direct the vote:	
(ii) Shared power to vote or to direct the vote:	1,400,000 <sup>(1) (2)</sup>
(iii) Sole power to dispose or to direct the disposition of:	
(iv) Shared power to dispose or to direct the disposition of:	1,400,000 <sup>(1) (2)</sup>

(1) The shares reported herein reflect the 1-for-8 reverse stock split of the Issuer's common stock which took effect on August 9, 2013.

- (2) Coventry LLC, the direct record holder of the shares reported herein is a wholly-owned subsidiary of Watson Labs and an indirect subsidiary of ultimate parent, Actavis plc. As a result of the direct or indirect subsidiary structure (as set forth immediately below), Watson Labs, Actavis, Inc., Actavis W.C., Actavis Capital, Actavis Ireland, WC 2 S.à r.l., WC 1 S.à r.l., Warner Chilcott and Actavis plc may be deemed to indirectly beneficially own the shares reported herein.

Entity Name (as defined under Item 2(a))	Relationship
Actavis plc	Ultimate Parent
Warner Chilcott	A wholly-owned subsidiary of Actavis plc
WC 1 S.à r.l.	A wholly-owned subsidiary of Warner Chilcott plc
WC 2 S.à r.l.	A wholly-owned subsidiary of Actavis WC 1 S.à r.l.

## SCHEDULE 13G/A

CUSIP No.: 197779101

Page 15 of 22 Pages

Entity Name (as defined under Item 2(a))	Relationship
Actavis Ireland	A wholly-owned subsidiary of Warner Chilcott plc
Actavis Capital	Owned 77.7% by Actavis Ireland; 22.3% by WC 2 S.à r.l.
Actavis W.C.	A wholly-owned subsidiary of Actavis Capital
Actavis, Inc.	A wholly-owned subsidiary of Actavis W.C.
Watson Labs	A wholly-owned subsidiary of Actavis, Inc.
Coventry LLC	A wholly-owned subsidiary of Watson Labs

(3) Based on 12,009,545 shares of Common Stock outstanding as of November 1, 2013, as reported in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013.

**Subsequent Events**

On July 2, 2010, pursuant to an agreement among the Issuer, Watson Pharmaceuticals, Inc. (now known as Actavis, Inc.) and Coventry Acquisition, Inc. (Coventry, Inc.), a Delaware corporation and wholly-owned subsidiary of Actavis, Inc., Coventry, Inc. acquired substantially all of the Issuer's assets primarily relating to the research, development, regulatory approval, manufacture, distribution, marketing, sale and promotion of pharmaceutical products containing progesterone as an active ingredient, including CRINONE 8% progesterone gel, PROCHIEVE 4% progesterone gel and PROCHIEVE 8% progesterone gel. In addition to the purchased assets, Coventry, Inc. received from the Issuer 11,200,000 restricted shares of the Issuer's common stock, \$0.01 par value per share, as initially reported on a Schedule 13G filed by Watson Pharmaceuticals, Inc. on July 12, 2010 in its capacity as the sole stockholder of Coventry, Inc.

As reported on Amendment No. 1 to Schedule 13G filed on February 14, 2012 by Watson Pharmaceuticals, Inc., pursuant to a contribution agreement between Watson Pharmaceuticals, Inc. and Watson Labs, Coventry, Inc. became a wholly-owned subsidiary of Watson Labs. A conversion of Coventry, Inc. from a Delaware corporation to a Delaware limited liability company was simultaneously effected, with Watson Labs retaining its interest in Coventry LLC as the sole member of Coventry LLC.

On January 24, 2013, Watson Pharmaceuticals, Inc. effected a corporate name change to Actavis, Inc.

On August 9, 2013, the Issuer effected a 1-for-8 reverse stock split of its common stock. As a result of the stock split, the 11,200,000 shares previously reported were adjusted to the 1,400,000 shares reported herein.

On October 1, 2013, Actavis plc became the successor registrant to Actavis, Inc. pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended.

On October 1, 2013, pursuant to a scheme of arrangement under Section 201, and a capital reduction under Sections 72 and 74, of the Irish Companies Act of 1963, among other things, the merger of a merger subsidiary with and into Actavis, Inc. was effected, with Actavis, Inc. surviving the merger. Following consummation of the merger, Actavis, Inc. became a wholly-owned subsidiary of Actavis plc.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 16 of 22 Pages

**Item 5. Ownership of Five Percent or Less of a Class:**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: " Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person:**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:**

Not applicable.

**Item 8. Identification and Classification of Members of the Group:** Not applicable.

**Item 9. Notice of Dissolution of Group:** Not applicable.

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 17 of 22 Pages

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2014

**ACTAVIS PLC**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**WARNER CHILCOTT PLC**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**ACTAVIS WC 1 S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 18 of 22 Pages

**ACTAVIS WC 2 S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager

**ACTAVIS IRELAND HOLDING LIMITED**

By: /s/ David A. Buchen  
David A. Buchen  
Director

**ACTAVIS CAPITAL S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager

**ACTAVIS W.C. HOLDING INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 19 of 22 Pages

**ACTAVIS, INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**WATSON LABORATORIES, INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**COVENTRY ACQUISITION, LLC,**

By: /s/ David A. Buchen  
David A. Buchen  
General Counsel and Secretary

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 20 of 22 Pages

**JOINT FILING AGREEMENT**

In accordance with Rule 13(d)-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached Amendment No. 2 to Schedule 13G and to all further amendments to such schedule.

IN WITNESS WHEREOF, the undersigned hereby executed this Agreement as of this February 13, 2014.

**ACTAVIS PLC**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**WARNER CHILCOTT PLC**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**ACTAVIS WC 1 S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager



SCHEDULE 13G/A

CUSIP No.: 197779101

Page 21 of 22 Pages

**ACTAVIS WC 2 S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager

**ACTAVIS IRELAND HOLDING LIMITED**

By: /s/ David A. Buchen  
David A. Buchen  
Director

**ACTAVIS CAPITAL S.À R.L.**

By: /s/ David A. Buchen  
David A. Buchen  
Class A Manager

By: /s/ Patrick van Denzen  
Patrick van Denzen  
Class B Manager

**ACTAVIS W.C. HOLDING INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

SCHEDULE 13G/A

CUSIP No.: 197779101

Page 22 of 22 Pages

**ACTAVIS, INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**WATSON LABORATORIES, INC.**

By: /s/ David A. Buchen  
David A. Buchen  
Chief Legal Officer Global and Secretary

**COVENTRY ACQUISITION, LLC,**

By: /s/ David A. Buchen  
David A. Buchen  
General Counsel and Secretary